The University of Lausanne is offering this technology for licensing or for collaboration.

The technology allows selective inhibition of T cell activation.

Development Phase :
Proof of principle

Patent Status :
A provisional patent application has been filed in October 2000.

Patent Attorney :
Mintz & Levin, Boston, USA

Novelty and Benefits :
The main feature of the current technology is that its mode of action is highly selective, and should therefore have less secondary effects than current approaches.

Additional information is available upon request.

Contact :

Marjory Hunt, PhD
tel: +41-21-314-4958
fax: +41-21-314-4957

Pactt

Office of Technology Transfer
University of Lausanne and University Hospitals
21, Rue du Bugnon
Ch-1005 Lausanne / Switzerland
e-mail : marjory.hunt@hospvd.ch

Selective Inhibition of T Cell Activation

(Reference Number IDF 15.00 )

The Technology :
The technology pertains to the use of a phospholipid that partitions in the plasma membrane microdomains (lipid rafts) of T cells, inhibiting their activation. The lipid selectively interferes with the recruitment of signaling molecules to the lipid rafts while having no effect on cell viability and raft integrity.

Applications :
Potential applications for this technology are pathologies due to irregular or inappropriate T cell activation.

Another application of this technology is lipid mediated drug delivery into the caveolae compartment.